Therapeutic Strateries Involving the Multidrug Resistance Phenotype: The MDRI Gene as Target, Chemoprotectant, and Selectable Marker in Gene Therapy

Advances in Pharmacology

Volumn 46, Issue C, 1999, Pages 1-42

  Aran, Josep M ^a   Pastan, Ira ^a   Gottesman, Michael M ^b  

^a Laboratoty of Molecular Biology

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN P;

ANIMAL; DRUG RESISTANCE; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; MOUSE; MULTIDRUG RESISTANCE; NEOPLASM; PHENOTYPE; PHYSIOLOGY; REVIEW; TRANSGENIC MOUSE;

ANIMALS; BIOLOGICAL MARKERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASMS; P-GLYCOPROTEIN; PHENOTYPE;

EID: 0032605117     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60468-8     Document Type: Chapter

References (213)

1. Akiyama S.-I., Fojo A., Hanover J.A., Pastan I., and Gottesman M.M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell. Mol. Genet. 11 (1985) 117-126
2. Aksentijevich I., Cardarelli C.O., Pastan I., and Gottesman M.M. Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity. Clin. Cancer Res. 2 (1996) 973-980
3. Aksentijevich I., Pastan I., Lunardi-Iskandar Y., Gallo R.C., Gottesman M.M., and Thierry A.R. In vitro and in vivo liposome-mediated gene transfer leads to human MDR1 expression in mouse bone marrow progenitor cells. Hum. Gene Ther. 7 (1996) 1111-1122
4. Alvarez M., Paull K., Monks A., Hose C., Lee J.S., Weinstein J., Grever M., Bates S., and Fojo T. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J. Clin. Invest. 95 (1995) 2205-2214
5. Allay J.A., Dumenco L.L., Koc O.N., Liu L., and Gerson S.L. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood 85 (1995) 3342-3351
6. Ambudkar S.V. Purification and reconstitution of functional human P-glycoprotein. J. Bioenerg. Biomembr. 27 (1995) 23-29
7. Ambudkar S.V., Lelong I.H., Zhang J.P., Cardarelli C.O., Gottesman M.M., and Pastan I. Partial purification and reconstitution of the human multidrug-resistance pump: Characterization of the drug-stimulatable ATP hydrolysis. Proc. Natl. Acad. Sci. USA 89 (1992) 8472-8476
8. Aran J.M., Germann U.A., Gottesman M.M., and Pastan I. Construction and characterization of a selectable multidrug resistance-glucocerebrosidase fusion gene. Cytokines Mol. Ther. 2 (1996) 47-57
9. Aran J.M., Gottesman M.M., and Pastan I. Drug-selected coexpression of human glucocerebrosidase and P-glycoprotein using a bicistronic vector. Proc. Natl. Acad. Sci. USA 91 (1994) 3176-3180
10. Aran J.M., Gottesman M.M., and Pastan I. Construction and characterization of bicistronic retroviral vectors encoding the multidrug transporter and β-galactosidase or green fluorescent protein. Cancer Gene Ther. 5 (1998) 195-206
11. Aran J.M., Licht T., Gottesman M.M., and Pastan I. Complete restoration of glucocerebrosidase deficiency in Gaucher fibroblasts using a bicistronic MDR retrovirus and a new selection strategy. Hum. Gene Ther. 7 (1996) 2165-2175
12. Bargou R.C., Jürchott K., Wagener C., Bergmann S., Metzner S., Bommert K., Mapara M.Y., Winzer K.J., Dietel M., Dörken B., and Royer H.D. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nature Med. 3 (1997) 447-450
13. Barranger J.A., and Ginns E.I. Glucosylceramide lipidoses: Gaucher disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D.D. (Eds). "The Metabolic Basis of Inherited Disease" 67 (1989), McGraw-Hill, New York 1677-1698
14. Bates S.E., Zhan Z., Dickstein B., Lee J.S., Scala S., Fojo A.T., Paull K., and Wilson W. Reversal of multidrug resistance. J. Hematother. 3 (1994) 219-223
15. Baudard M., Flotte T.R., Aran J.M., Thierry A.R., Pastan I., Pang M.G., Kearns W.G., and Gottesman M.M. Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: Efficient promoter activity of AAV sequences and in vivo delivery via liposomes. Hum. Gene Ther. 7 (1996) 1309-1322
16. Baum C., Eckert H.G., Stockschlader M., Just U., Hegewisch-Becker S., Hildinger M., Uhde A., John J., and Ostertag W. Improved retroviral vectors for hematopoietic stem cell protection and in vivo selection. J. Hematother. 5 (1996) 323-329
17. Baum C., Hegewisch-Becker S., Eckert H.G., Stocking C., and Ostertag W. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J. Virol. 69 (1995) 7541-7547
18. Beck W.T., Danks M.K., Wolverton J.S., Granzen B., Chen M., Schmidt C.A., Bugg B.Y., Friche E., and Suttle D.P. Altered DNA topoisomerase II in multidrug resistance. Cytotechnology 11 (1993) 115-119
19. Bertolini F., DeMonte L., Corsini C., Lazzari L., Lauri E., Soligo D., Ward M., Bank A., and Malavasi F. Retrovirus-mediated transfer of the multidrug resistance gene into human haemopoietic progenitor cells. Br. J. Haematol. 88 (1994) 318-324
20. Bertram J., Palfner K., Killian M., Brysch W., Schlingensiepen K.H., Hiddemann W., and Kneba M. Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes. Anticancer Drugs 6 (1995) 124-134
21. Beutler E. Gaucher disease: New molecular approaches to diagnosis and treatment. Science 256 (1992) 794-799
22. Bierman P.J., Bagin R.G., Jagannath S., Vose J.M., Spitzer G., Kessinger A., Dicke K.A., and Armitage J.O. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients. Ann. Oncol. 4 (1993) 767-773
23. Blau C.A., Neff T., and Papayannopoulou T. Cytokine prestimulation as a gene therapy strategy: Implications for using the MDR1 gene as a dominant selectable marker. Blood 89 (1997) 146-154
24. Bodine D.M., Karlsson S., and Nienhuis A.W. Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 86 (1989) 8897-8901
25. Bodine D.M., McDonagh K.T., Seidel N.E., and Nienhuis A.W. Survival and retrovirus infection of murine hematopoietic stem cells in vitro: Effects of 5-FU and method of infection. Exp. Hematol. 19 (1991) 206-212
26. Bodine D.M., Seidel N.E., Gale M.S., Nienhuis A.W., and Orlic D. Efficient retrovirus transduction of mouse pluripotent hematopoietic stem cells mobilized into the peripheral blood by treatment with granulocyte colony-stimulating factor and stem cell factor. Blood 84 (1994) 1482-1491
27. Bonini C., Ferrari G., Verzeletti S., Servida P., Zappone E., Ruggieri L., Ponzoni M., Rossini S., Mavilio F., Traversari C., and Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276 (1977) 1719-1724
28. Boyd M., and Paull K. Some practical considerations and applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen. Drug Dev. Res. 34 (1995) 91-109
29. Bradley G., and Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev. 13 (1994) 223-233
30. Bruggemann E.P., Germann U.A., Gottesman M.M., and Pastan I. Two different regions of P-glycoprotein are photoaffinity labeled by azidopine. J. Biol. Chem. 264 (1989) 15483-15488
31. Brugger W., Heimfeld S., Berenson R.J., Mertelsmann R., and Kanz L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N. Engl. J. Med. 333 (1995) 283-287
32. Bunting K.D., Lindahl R., and Townsend A.J. Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase. J. Biol. Chem. 269 (1994) 23197-23203
33. Cardarelli C.O., Aksentijevich I., Pastan I., and Gottesman M.M. Differential effects of P-glycoprotein inhibitors of NIH 3T3 cells transfected with wild-type (G 185) or mutant (V 185) multidrug transporters. Cancer Res. 55 (1995) 1086-1091
34. Chambers T.C., Pohl J., Raynor R.L., and Kuo J.F. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J. Biol. Chem. 268 (1993) 4592-4595
35. Chan H.S.L., Thorner P.S., Ghaddad, and Ling V. Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcomas of childhood. J. Clin. Oncol. 8 (1990) 689-704
36. Chaudhary P.M., and Roninson I.B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst. 85 (1993) 632-639
37. Chen C.-J., Chin C.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., and Roninson I.B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47 (1986) 381-389
38. Chen G., and Waxman D.J. Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. Biochem. Pharmacol. 49 (1995) 1691-1701
39. Cherif A., and Farquhar D. N-(5,5-diacetoxypent-1-yl)doxorubicin: A new intensely potent doxorubicin analogue. J. Med. Chem. 35 (1992) 3208-3214
40. Chin K.-V., Tanaka S., Darlington G., Pastan I., and Gottesman M.M. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J. Biol. Chem. 265 (1990) 221-226
41. Chin K.-V., Ueda K., Pastan I., and Gottesman M.M. Modulation of the activity of the promoter of the human MDR1 gene by Ras and p53. Science 255 (1992) 459-462
42. Choi K., Chen C.-J., Kriegler M., and Roninson I.B. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 53 (1989) 519-529
43. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., and Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258 (1992) 1650-1654
44. Corey C.A., DeSilva A.D., Holland C.A., and Williams D.A. Serial transplantation of methotrexate-resistant bone marrow: Protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 76 (1990) 337-343
45. Cornwell M.M., and Smith D.E. A signal transduction pathway for activation of the mdr1 promoter involves the protooncogene c-raf kinase. J. Biol. Chem. 268 (1993) 15347-15350
46. Cosset F.-L., and Russell S.J. Targeting retrovirus entry. Gene Ther. 3 (1996) 946-956
47. Cucco C., and Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res. 56 (1996) 4332-4337
48. Cullen B.R., Lomedico P.T., and Ju G. Transcriptional interference in avian retroviruses: Implications for the promoter insertion model of leukaemogenesis. Nature 307 (1984) 241-245
49. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim. Biophys. Acta 323 (1973) 466-483
50. De la Flor-Weiss E., Richardson C., Ward M., Himmelstein A., Smith L., Podda S., Gottesman M.M., Pastan I., and Bank A. Transfer and expression of the human multidrug resistance gene in mouse erythroleukemia cells. Blood 80 (1992) 3106-3111
51. Deisseroth A.B., Kavanagh J., and Champlin R. Clinical protocol: Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: A pilot trial. Hum. Gene Ther. 5 (1994) 1507-1522
52. Dey S., Ramachandra M., Pastan I., Gottesman M.M., and Ambudkar S.V. Evidence for two non-identical drug interaction sites in the human P-glycoprotein. Proc. Natl. Acad. Sci. USA 94 (1997) 10594-10599
53. Dirks W., Wirth M., and Hauser H. Dicistronic transcription units for gene expression in mammalian cells. Gene 129 (1993) 247-249
54. Doroshow J.H., Metz M.Z., Matsumoto L., Winters K.A., Sakai M., Muramatsu M., and Kane S.E. Transduction of NIH 3T3 cells with a retrovirus carrying both human MDR1 and glutathione S-transferase (produces broad-range multidrug resistance. Cancer Res. 55 (1995) 4073-4078
55. Dunbar C.E., Seidel N.E., Doren S., Sellers S., Cline A.P., Metzger M.E., Agricola B.A., Donahue R.E., and Bodine D.M. Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor. Proc. Natl. Acad. Sci. USA 93 (1996) 11871-11876
56. Eckert H.G., Stockschlader M., Just U., Hegewisch-Becker S., Grez M., Uhde A., Zander A., Ostertag W., and Baum C. High-dose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral vectors. Blood 88 (1996) 3407-3415
57. Eggermont J., and Proudfoot N.J. Poly (A) signals and transcriptional pause sites combine to prevent interference between RNA polymerase II promoters. EMBO J. 12 (1993) 2539-2548
58. Eijdems E.W., Borst P., Jongsma A.P., DeJong S., DeVries E.G., Van Groenigen M., Versantvoort C.H., Nieuwint A.W., and Baas F. Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: Dissection of a compound MDR phenotype. Proc. Natl. Acad. Sci. USA 89 (1992) 3498-3502
59. Emerman M., and Temin H.H. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 39 (1984) 459-467
60. Emerman M., and Temin H.H. Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol. Cell. Biol. 6 (1986) 792-800
61. Endicott J.A., and Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58 (1989) 137-171
62. Evans G.L., Ni B., Hrycyna C.A., Chen D., Ambudkar S.V., Pastan I., Germann U.A., and Gottesman M.M. Heterologous expression systems for P-glycoprotein: E. coli, yeast, and baculovirus. J. Bioenerg. Biomembr. 27 (1995) 43-52
63. Feldman E., Arlin Z., Ahmed T., Mittelman A., Puccio C., Chun H., Cook P., and Baskind P. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 6 (1992) 1185-1188
64. FitzGerald D.J., Willingham M.C., Cardarelli C.O., Hamada H., Tsuruo T., Gottesman M.M., and Pastan I. A monoclonal anibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc. Natl. Acad. Sci. USA 84 (1987) 4288-4292
65. + peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood 85 (1995) 566-574
66. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., and Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA 84 (1987) 265-269
67. Fojo A.T., Whang-Pang J., Gottesman M.M., and Pastan I. Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proc. Natl. Acad. Sci. USA 82 (1985) 7661-7665
68. Ford J.M., and Hait W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42 (1990) 155-199
69. Freije J.M., Lawrence J.A., Hollingshead M.G., De La Rosa A., Narayanan V., Grever M., Sauaville E.A., Paull K., and Steeg P.S. Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines. Nature Med. 3 (1997) 395-401
70. Friedman H.S., Colvin O.M., Kaufmann S.H., Ludeman S.M., Bullock N., Bigner D.D., and Griffith O.W. Cyclophosphamide resistance in medulloblastoma. Cancer Res. 52 (1992) 5373-5378
71. Fruehauf S., Boessen J.J., Breems D.A., Hoft R., Hundsdorfer P., Zeller W.J., Lowenberg B., Ploemacher R.E., Haas R., and Valerio D. Retroviral transfer of the multidrug resistance-1 gene into lineage-committed and primitive hemopoietic cells. Stem Cells 13 (1995) 93-99
72. Fruehauf S., Breems D.A., Knaan-Shanzer S., Brouwer K.B., Haas R., Lowenberg B., Nooter K., Ploemacher R.E., Valerio D., and Boesen J.J. Frequency analysis of multidrug resistance-1 gene transfer into human primitive hematopoietic progenitor cells using the cobblestone area-forming cell assay and detection of vector-mediated P-glycoprotein expression by rhodamine-123. Hum. Gene Ther. 7 (1996) 1219-1231
73. Gabrilove J.L. Colony-stimulating factors: Clinical status. Important Adv. Oncol. 13 (1991) 215-237
74. Galski H., Sullivan M., Willingham M.C., Chin K.V., Gottesman M.M., Pastan I., and Merlino G.T. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: Resistance to daunomycin-induced leukopenia. Mol. Cell. Biol. 9 (1989) 4357-4363
75. Gazit G., Kane S.E., Nichols P., and Lee A.S. Use of stress-inducible grp78/BiP promoter in targeting high level gene expression in fibrosarcoma in vivo. Cancer Res. 55 (1995) 1660-1663
76. Germann U.A. Molecular analysis of the multidrug transporter. Cytotechnology 12 (1993) 33-62
77. Germann U.A., Chambers T.C., Ambudkar S.V., Licht T., Cardarelli C.O., Pastan I., and Gottesman M.M. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J. Biol. Chem. 271 (1996) 1708-1716
78. Germann U.A., Chin K.-V., Pastan I., and Gottesman M.M. Retroviral transfer of a chimeric multidrug-resistance-adenosine deaminase gene. FASEB J. 4 (1990) 1501-1507
79. Germann U.A., Gottesman M.M., and Pastan I. Expression of a multidrug resistance-adenosine deaminase fusion gene. J. Biol. Chem. 264 (1989) 7418-7424
80. Goldstein L.J. Clinical reversal of drug resistance. In: Ozols R.F. (Ed). "Current Problems in Cancer" 19 (1995), Mosby-Year Book, St. Louis, MO 67-124
81. Goldstein L.J., Galski H., Fojo A., Willingham M., Lai S.-I., Gadzar A., Pirker R., Green A., Crist W., Brodeur G.M., Lieber M., Cossman J., Gottesman M.M., and Pastan I. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 81 (1989) 116-124
82. Gottesman M.M., and Pastan I. The multidrug transporter, a double-edged sword. J. Biol. Chem. 263 (1988) 12163-12166
83. Gottesman M.M., and Pastan I. The multidrug resistance (MDR1) gene as a selectable marker in gene therapy. In: Cohen-Haguenauer O., and Boiron M. (Eds). "Human Gene Transfer" 219 (1991), Colloque INSERM/John Libbey Eurotext Ltd., London 185-191
84. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62 (1993) 385-427
85. Gottesman M.M., Ambudkar S.V., Ni B., Aran J.M., Sugimoto Y., Cardarelli C.O., and Pastan I. Exploiting multidrug resistance to treat cancer. Cold Spring Harbor Symp. Quant. Biol. 59 (1994) 677-683
86. Gottesman M.M., Germann U.A., Aksentijevich I., Sugimoto Y., Cardarelli C.O., and Pastan I. Gene transfer of drug resistance genes: Implications for cancer therapy. Ann. N. Y. Acad. Sci. 716 (1994) 126-139
87. Gottesman M.M., Hrycyna C.A., Schoenlein P.V., Germann U.A., and Pastan I. Genetic analysis of the multidrug transporter. Annu. Rev. Genet. 29 (1995) 607-649
88. Gottesman M.M., Mickisch G.H., and Pastan I. In vivo models of P-glycoprotein-mediated multidrug resistance. In: Goldstein L.J., and Ozols F.R. (Eds). "Anticancer Drug Resistance: Advances in Molecular and Clinical Research" (1994), Kluwer, Boston 107-128
89. Greenbaum M., Letourneau S., Assar H., Schecter R.L., Batist G., and Cournoyer D. Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers alkylating drug resistance in NIH 3T3 mouse fibroblasts. Cancer Res. 54 (1994) 4442-4447
90. Greenberger L.M. Major photoaffinity drug labeling sites for iodoarylazidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domain-6 and domain-12. J. Biol. Chem. 268 (1993) 11417-11425
91. Grogan T.M., Guptill V., and Scheper R. Altered cell adhesion molecule (CAM) in P-glycoprotein rich myeloma plasma cells. J. Cell. Biol. 111 (1990) 156a
92. Gros P., Ben Neriah Y., Croop J., and Housman D.E. Isolation and characterization of a complementary DNA that confers multidrug resistance. Nature 323 (1986) 728-731
93. Guild B.C., Mulligan R.C., Gros P., and Housman D.E. Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection. Proc. Natl. Acad. Sci. USA 85 (1988) 1595-1599
94. Hamada H., and Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 83 (1986) 7785-7789
95. Hanania E.G., and Deisseroth A.B. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther. 1 (1994) 21-25
96. Hanania E.G., and Deisseroth A.B. Simultaneous genetic chemoprotection of normal marrow cells and genetic chemosensitization of breast cancer cells in a mouse cancer gene therapy model. Clin. Cancer Res. 3 (1997) 281-286
97. Hanania E.G., Fu S., Roninson I., Zu Z., Gottesman M.M., and Deisseroth A.B. Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther. 2 (1995) 279-284
98. Hanania E.G., Giles R.E., Kavanagh J., Ellerson D., Zu Z., Wang T., Su Y., Kudelka A., Rahman Z., Holmes F., Hortobagyi G., Claxton D., Bachier C., Thall P., Cheng S., Hester J., Ostrove J.M., Bird R.E., Chang A., Korbling M., Seong D., Cote R., Holzmayer T., Mechetner E., Heimfeld S., Berenson R., Burtness B., Edwards C., Bast R., Andreeff M., Champlin R., and Deisseroth A.B. Results of MDR1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc. Natl. Acad. Sci. USA 93 (1996) 15346-15351
99. Hanania E.G., Kavanagh J., Giles R.E., Kudelka A., Rahman Z., Holmes F., Hortobagyi G., Hamer J., Calvert L., Finnegan M.B., Mante R., Ellerson D., Geisler D., Wang T., Su Y., Zu Z., Chen N., Berenson R., Heimfeld S., Claxton D., Mechetner E., Holzmayer T., Mehra R., Cote R., Champlin R., and Deisseroth A.B. Rapid neutrofil recovery in autologous transplants using cells that have been exposed to a multiple drug resistance (MDR-1) retroviral vector. Blood 86 (1995) A1833
100. Harris L.C., Marathi U.K., Edwards C.C., Houghton P.J., Srivastava D.K., Vanin E.F., Sorrentino B.P., and Brent T.P. Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity. Clin. Cancer Res. 1 (1995) 1359-1365
101. Hegewisch-Becker S., Hanania E.G., Fu S., Korbling M., Deisseroth A.B., and Andreeff M. Transduction of MDR1 into human and mouse haemopoietic progenitor cells: Use of rhodamine (Rh123) to determine transduction frequency and in vivo selection. Br. J. Haematol. 90 (1995) 876-883
102. Hesdorffer C., Antman K., Bank A., Fetell M., Mears G., and Begg M. Clinical protocol: Human MDR gene transfer in patients with advanced cancer. Hum. Gene Ther. 5 (1994) 1151-1160
103. Higgins C.F. ABC transporters: From microorganisms to man. Annu. Rev. Cell. Biol. 8 (1992) 67-113
104. Higgins C.F., and Gottesman M.M. Is the multidrug transporter a flippase?. Trends Pharmacol. Sci. 17 (1992) 18-21
105. Ho S.P., Britton D.H., Stone B.A., Behrens D.L., Leffer L.M., Hobbs F.W., Miller J.A., and Trainor G.L. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res. 24 (1996) 1901-1907
106. Hofmann G.A., and Mattern M.R. Topoisomerase II in multiple drug resistance. Cytotechnology 12 (1993) 137-154
107. Holm P.S., Scanlon K.J., and Dietel M. Reversion of multidrug resistance in the P-glycoprotein cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br. J. Cancer 70 (1994) 239-243
108. Homolya L., Holló Z., Germann U.A., Pastan I., Gottesman M.M., and Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 268 (1993) 21493-21496
109. Hrycyna C.A., Zhang S., Ramachandra M., Ni B., Pastan I., and Gottesman M.M. Functional and molecular characterization of the human multidrug transporter. In: Gupta S., and Tsuruo T. (Eds). "Multidrug Resistance in Cancer Cells" (1996), Wiley, Sussex, UK 29-38
110. Jiang X.R., Kelsey S.M., Wu Y.L., and Newland A.C. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833. Br. J. Haematol. 90 (1995) 375-383
111. Juliano R.L., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455 (1976) 152-162
112. Kane S.E., Reinhard D.H., Fordis C.M., Pastan I., and Gottesman M.M. A new vector using the human multidrug resistance gene as a selectable marker enables overexpression of foreign genes in eukaryotic cells. Gene 84 (1989) 439-446
113. Kane S.E., Troen B.R., Gal S., Ueda K., Pastan I., and Gottesman M.M. Use of a cloned multidrug resistance gene for coamplification and overproduction of major excreted protein, a transformation-regulated secreted acid protease. Mol. Cell. Biol. 8 (1988) 3316-3321
114. Karlsson S. Treatment of genetic defects in hematopoietic cell function by gene transfer. Blood 78 (1991) 2481-2492
115. Kartner N., Evernden-Porelle D., Bradley G., and Ling V. Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature 316 (1985) 820-823
116. Kaufman R.J., Davies M.V., Wasley L.C., and Michnick D. Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus. Nucleic Acids Res. 19 (1991) 4485-4490
117. Kiehntopf M., Brach M.A., Licht T., Karawajew L., Kirschning C., and Herrmann F. Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J. 13 (1994) 4645-4652
118. Lee C.G.L., Jeang K.-T., Martin M.A., Pastan I., and Gottesman M.M. Efficient long-term co-expression of a hammerhead ribozyme targeted to the U5 region of HIV-1 LTR by linkage to the multidrug-resistance gene. Antisense Nucleic Acid Drug Dev. 7 (1997) 511-522
119. Lee J.-S., Paull K., Alvarez M., Hose C., Monks A., Grever M., Fojo A.T., and Bates S.E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46 (1994) 627-638
120. Li M.X., Banerjee D., Zhao S.C., Schweitzer B.I., Mineishi S., Gilboa E., and Bertino J.R. Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood 83 (1994) 3403-3408
121. Licht T., Aksentijevich I., Gottesman M.M., and Pastan I. Efficient expression of functional human MDR1 gene in murine bone marrow after transduction of purified hematopoietic stem cells. Blood 86 (1995) 111-121
122. Liu C., Qureshi I.A., Ding X., Shan Y., Huang Y., Xie Y., and Ji M. Modulation of multidrug resistance gene (mdr-1) with antisense oligodeoxynucleotides. Clin. Sci. 91 (1996) 93-98
123. Loo T.W., and Clarke D.M. Functional consequences of phenylalanine mutations in the predicted transmembrane domain of P-glycoprotein. J. Biol. Chem. 268 (1993) 19965-19972
124. Loo T.W., and Clarke D.M. Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. J. Biol. Chem. 268 (1993) 3143-3149
125. Loo T.W., and Clarke D.M. Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. J. Biol. Chem. 269 (1994) 7243-7248
126. Loo T.W., and Clarke D.M. Mutations to aminoacids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry 33 (1994) 14049-14057
127. Markowitz D., Goff S., and Bank A. A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J. Virol. 62 (1988) 1120-1124
128. McLachlin J.R., Eglitis M.A., Ueda K., Kantoff P.W., Pastan I.H., Anderson W.R., and Gottesman M.M. Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. J. Natl. Cancer Inst. 82 (1990) 1260-1263
129. Metz M.Z., Best D.M., and Kane S.E. Harvey murine sarcoma virus/MDR1 retroviral vectors: Efficient virus production and foreign gene transduction using MDR1 as a selectable marker. Virology 208 (1995) 634-643
130. Metz M.Z., Matsumoto L., Winters K.A., Doroshow J.H., and Kane S.E. Bicistronic and two-gene retroviral vectors for using MDR1 as a selectable marker and a therapeutic gene. Virology 217 (1996) 230-241
131. Mickisch G.H., and Schroeder F.H. From laboratory expertise to clinical practice: multidrug-resistance-based gene therapy becomes available for urologists. World J. Urol. 12 (1994) 104-111
132. Mickisch G.H., Aksentijevich I., Schoenlein P.V., Goldstein L.J., Galski H., Stahle C., Sachs D.H., Pastan I., and Gottesman M.M. Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 79 (1992) 1087-1093
133. Mickisch G.H., Licht T., Merlino G.T., Gottesman M.M., and Pastan I. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: Efficacy, potency and toxicity. Cancer Res. 51 (1991) 5417-5424
134. Mickisch G.H., Merlino G.T., Galski H., Gottesman M.M., and Pastan I. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc. Natl. Acad. Sci. USA 88 (1991) 547-551
135. Mickisch G.H., Pai L.H., Gottesman M.M., and Pastan I. Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice. Cancer Res. 52 (1992) 4427-4432
136. Mickisch G.H., Pai L.H., Siegsmund M., Campain J., Gottesman M.M., and Pastan I. Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice. J. Urol. 149 (1993) 174-178
137. Mickisch G.H., Pastan I., and Gottesman M.M. Multidrug resistant transgenic mice as a novel pharmacologic tool. BioEssays 13 (1991) 381-387
138. Mickisch G.H., Rahman A., Pastan I., and Gottesman M.M. Increased effectiveness of liposome-encapsulated doxorubicin in multidrug-resistant transgenic mice compared with free doxorubicin. J. Natl. Cancer Inst. 84 (1992) 804-805
139. Mickley L.A., Bates S.E., Richert N.D., Currier S., Tanaka S., Foss F., Rosen N., and Fojo A.T. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J. Biol. Chem. 264 (1989) 18031-18040
140. Miller A.D., and Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6 (1986) 2895-2902
141. Miller A.D., Miller D.G., Garcia J.V., and Lynch C.M. Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 217 (1993) 581-599
142. Morgan R.A., Couture L., Elroy-Stein O., Ragheb J., Moss B., and Anderson W.F. Retroviral vectors containing putative internal ribosome entry sites: Development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res. 20 (1992) 1293-1299
143. Moritz T., Mackay W., Glassner B.J., Williams D.A., and Samson L. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res. 55 (1995) 2608-2614
144. Morris D.I., Greenberger L.M., Bruggemann E.P., Cardarelli C., Gottesman M.M., Pastan I., and Seamon K.B. Localization of the forskolin labeling sites to both halves of P-glycoprotein: Similarity of the sites labeled by forskolin and prazosin. Mol. Pharmacol. 46 (1994) 329-337
145. Nakashima E., Matsushita R., Negishi H., Nomura M., Harada S., Yamamoto H., Miyamoto K., and Ichimura F. Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotide. J. Pharm. Sci. 84 (1995) 1205-1209
146. Ng W.F., Sarangi F., Zastawny R.L., Veinot-Drebot L., and Ling V. Identification of members of the P-glycoprotein multigene family. Mol. Cell. Biol. 9 (1989) 1224-1232
147. Nolta J.A., Smogorzewska E.M., and Kohn D. Analysis of optimal conditions for retroviral-mediated transduction of primitive human hematopoietic cells. Blood 86 (1995) 101-110
148. Noonan K.E., Beck C., Holzmayer T.A., Chin J.E., Wunder J.S., Andrulis I.L., Gadzar A.F., Willman C.L., Griffith B., van Hoff D.D., and Roninson I.B. Quantitative analysis of mdr1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. USA 87 (1990) 7160-7164
149. O'Shaughnessy J.A., Cowan K.H., Nienhuis A.W., McDonagh K.T., Sorrentino B.P., Dunbar C.E., Chiang Y., Wilson W., Goldspiel B., Kohler D., Cottler-Fox M., Leitman S., Gottesman M.M., Pastan I., Denicoff A., Noone M., and Gress R. Clinical protocol: Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum. Gene Ther. 5 (1994) 891-911
150. Ogawa M. Differentiation and proliferation of stem cells. Blood 81 (1993) 2844-2853
151. Ohshima T., Murray G.J., Swaim W.D., Longenecker G., Quirk J.M., Cardarelli C.O., Sugimoto Y., Pastan L., Gottesman M.M., Brady R.O., and Kulkarni A.B. Alpha-galactosidase A deficient mice: A model of Fabry disease. Proc. Natl. Acad. Sci. USA 94 (1997) 2540-2544
152. Olsen J.C., Johnson L.G., Wong-Sun M.L., Moore K.L., Swanstrom R., and Boucher R.C. Retrovirus-mediated gene transfer to cystic fibrosis airway epithelial cells: Effect of selectable marker sequences on long-term expression. Nucleic Acids Res. 21 (1993) 663-669
153. Padmanabhan R., Tsuruo T., Kane S.E., Willingham M.C., Howard B.H., Gottesman M.M., and Pastan I. Magnetic-affinity cell sorting of human multidrug-resistant cells. J. Natl. Cancer Inst. 83 (1991) 565-569
154. Pastan L., Gottesman M.M., Ueda K., Lovelace E., Rutherford A., and Willingham M.C. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl. Acad. Sci. USA 85 (1988) 4486-4490
155. Podda S., Ward M., Himelstein A., Richardson C., Flor-De la Weiss E., Smith L., Gottesman M.M., Pastan L., and Bank A. Transfer and expression of the human multiple drug resistance gene into live mice. Proc. Natl. Acad. Sci. USA 89 (1992) 9676-9680
156. Ramachandra M., Ambudkar S.V., Gottesman M.M., Pastan L., and Hrycyna C.A. Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system. Mol. Biol. Cell 7 (1996) 1485-1498
157. Raviv Y., Pollard H.B., Bruggemann E.P., Pastan L., and Gottesman M.M. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem. 265 (1990) 3975-3980
158. Richert N.D., Aldwin L., Nitecki D., Gottesman M.M., and Pastan I. Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry 27 (1988) 7607-7613
159. Roninson I.B. In: Roninson I.B. (Ed). "Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells" (1991), Plenum, New York
160. Rund D., Dagan M., Dalyot N., Schoenlein P., Gottesman M.M., and Oppenheim A. Efficient transduction of human hematopoietic cells with the human multidrug resistance gene 1 (MDR1) via SV40 pseudovirions. Human Gene Ther. 9 (1998) 649-657
161. Russo D., Michelutti A., Melli C., Damiani D., Michieli M.G., Candoni A., Zhou D.C., Marie J.P., Zittoun R., and Baccarani M. MDR-related P 170-glycoprotein modulates cytotoxic activity of homoharringtonine. Leukemia 9 (1995) 513-516
162. Safa A.R., Stern R.K., Choi K., Agresti M., Tamai I., Mehta N.D., and Roninson I.B. Molecular basis of preferential resistance to colchicine in multidrug-resistant cells conferred by Gly-185→Val-185 substitution in P-glycoprotein. Proc. Natl. Acad. Sci. USA 87 (1990) 7225-7229
163. Salmons B., and Günzburg W.H. Targeting of retroviral vectors for gene therapy. Hum. Gene Ther. 4 (1993) 129-141
164. Scaggiante B., Morassutti C., Tolazzi G., Michelutti A., Baccarani M., and Quandrifoglio F. Effect of unmodified triple helix-forming oligodeoxyribonucleotide targeted to human multidrug-resistance gene mdrl in MDR cancer cells. FEBS Lett. 352 (1994) 380-384
165. Scanlon K.J., Ishida H., and Kashani-Sabet M. Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc. Natl. Acad. Sci. USA 91 (1994) 11123-11127
166. Schinkel A.H., and Borst P. Multidrug resistance mediated by P-glycoproteins. Semin. Cancer Biol. 2 (1991) 213-226
167. Schinkel A.H., Kemp S., Dolle M., Rudenko G., and Wagenaar E. N-Glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J. Biol. Chem. 268 (1993) 7474-7481
168. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A.A.M., van Deemter L., Smit J.J.M., van der Valk M.A., Vooreouw A.C., Spits H., van Tellingen O., Zijlmans J.M., Fibbe W.E., and Borst P. Normal viability and altered pharmacokinetics in mice lacking MDR1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA 94 (1997) 4028-4032
169. Schnierle B.S., and Groner B. Retroviral targeted delivery. Gene Ther. 3 (1996) 1069-1073
170. Sela S., Husain S.R., Pearson J.W., Longo D.L., and Rahman A. Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil. J. Natl. Cancer Inst. 87 (1995) 123-128
171. Shen D.-W., Cardarelli C., Hwang J., Cornwell M., Richert N., Ishii S., Pastan I., and Gottesman M.M. Multiple drug resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin or vinblastine show changes in expression of specific proteins. J. Biol. Chem. 261 (1986) 7762-7770
172. Shen D.-W., Fojo A., Chin J.E., Roninson I.B., Richert N., Pastan I., and Gottesman M.M. Human multidrug-resistant cell lines: Increased MDR1 expression can precede gene amplification. Science 232 (1986) 643-645
173. Shen D.-W., Pastan I., and Gottesman M.M. In situ hybridization analysis of acquisition and loss of the human multidrug-resistance gene. Cancer Res. 48 (1988) 4334-4339
174. Sikic B.I. Modulation of multidrug resistance: At the threshold. J. Clin. Oncol. 11 (1993) 1629-1635
175. Simon S.M., and Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. USA 91 (1994) 3497-3504
176. Sokolic R.A., Sekhsaria S., Sugimoto Y., Whiting-Theobald N., Linton G.F., Li F., Gottesman M.M., and Malech H.L. A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression. Blood 87 (1996) 42-50
177. Sola J.E., and Colombani P.M. Modulation of multidrug resistance with antisense oligodeoxynucleotide to mdrl mRNA. Ann. Surg. Oncol. 3 (1996) 80-85
178. Sorrentino B.P., Brandt S.J., Bodine D., Gottesman M.M., Pastan I., Cline A., and Nienhuis A.W. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257 (1992) 99-103
179. Sorrentino B.P., McDonagh K.T., Woods D., and Orlic D. Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice. Blood 86 (1995) 491-501
180. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.F.K., Bost P., Nooijen W.J., Beijnen J.H., and van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94 (1997) 2031-2035
181. Stein D.-W., Cardarelli C.O., Pastan I., and Gottesman M.M. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol. Pharmacol. 45 (1994) 763-772
182. Sugimoto Y., Aksentijevich I., Gottesman M.M., and Pastan I. Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site. Biotechnology 12 (1994) 694-698
183. Sugimoto Y., Aksentijevich I., Murray G.J., Brady R.O., Pastan I., and Gottesman M.M. Retroviral coexpression of a multidrug resistance gene (MDR1) and human a-galactosidase A for gene therapy of Fabry disease. Hum. Gene Ther. 6 (1995) 905-915
184. Sugimoto Y., Hrycyna C.A., Aksentijevich I., Pastan I., and Gottesman M.M. Coexpression of a multidrug-resistance gene (MDR1) and herpes simplex virus thymidine kinase gene as part of a bicistronic messenger RNA in a retrovirus vector allows selective killing of MDR1 -transduced cells. Clin. Cancer Res. 1 (1995) 447-457
185. Sugimoto Y., Sato S., Tsukahara S., Suzuki M., Okochi E., Gottesman M.M., Pastan I., and Tsuruo T. Coexpression of a multidrug resistance gene (MDR1) and herpes simplex virus thymidine kinase gene in a bicistronic retroviral vector Ha-MDR-lRES-TK allows selective killing of MDR1-transduced human tumors transplanted in nude mice. Cancer Gene Ther. 4 (1997) 51-58
186. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84 (1987) 7735-7738
187. Thierry A.R., Rahman A., and Dritschilo A. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem. Biophys. Res. Commun. 190 (1993) 952-960
188. Thierry A.R., Vige D., Coughlin S.S., Belli J.A., Dritschilo A., and Rahman A. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J. 7 (1993) 572-579
189. Thorgeirsson S.S., Huber B.E., Sorrell S., Fojo A.T., Pastan I., and Gottesman M.M. Expression of the multidrug-resistance gene in hepatocarcinogenesis and regenerating rat liver. Science 236 (1987) 1120-1122
190. Tsuruo T., Hamada H., Sato S., and Heike Y. Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. Jpn. J. Cancer Res. 80 (1989) 627-631
191. Tsuruo T., Iida H., Tsukagoshi S., and Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41 (1981) 1967-1972
192. Tsuruo T., and Tomida A. Multidrug resistance. Anti-Cancer Drugs 6 (1995) 213-218
193. Ueda K., Cardarelli C., Gottesman M.M., and Pastan I. Expression of a full-length cDNA for the human "MDR1" (P-glycoprotein) gene confers multidrug resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA 84 (1987) 3004-3008
194. Ueda K., Clark D.P., Chen C.-J., Roninson I.B., Gottesman M.M., and Pastan I. The human multidrug resistance (mdr1) gene: cDNA cloning and transcription initiation. J. Biol. Chem. 262 (1987) 505-508
195. Ueda K., Yamano Y., Kioka N., Kakehi Y., Yoshida O., Gottesman M.M., Pastan I., and Komano T. Detection of multidrug resistance (MDR1) gene RNA expression in human tumors by a sensitive ribonuclease protection assay. Jpn. J. Cancer Res. 80 (1989) 1127-1132
196. Ulich T.R., del Castillo J., Yin S., Swift S., Padilla D., Senaldi G., Bennett L., Shutter J., Bogenberger J., Sun D., Samal B., Shimamoto G., Lee R., Steinbrink R., Boone T., Sheridan W.T., and Hunt P. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 86 (1995) 971-976
197. Urbatsch I.L., and Senior A.E. Effects of lipids on ATPase activity of purified Chinese hamster P-glycoprotein. Arch. Biochem. Biophys. 316 (1995) 135-140
198. van Helvoort A., Smith A.J., Sprong H., Fritzsche I., Schinkel A.H., Borst P., and van Meer G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87 (1996) 507-517
199. Walther W., Wendt J., and Stein U. Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. Gene Ther. 4 (1997) 544-552
200. Wang Y.H., Motoji T., Motomura S., Shiozaki H., Tsuruo T., and Mizoguchi H. Recovery of drug sensitivity by MS-209, a new multidrug resistance-reversing agent, on acute myelogenous leukaemic blasts and K562 cells resistant to adriamycin cell line. Eur. J. Haematol. 58 (1997) 186-194
201. + cells. Blood 84 (1994) 1408-1414
202. Watanabe T., Naito M., Kokubu N., and Tsuruo T. Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies. J. Natl. Cancer Inst. 89 (1997) 512-518
203. Watanabe T., Tsuge H., Tomoko O., Naito M., and Tsuruo T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol. 34 (1995) 235-241
204. Weaver J.L., Ine P.S., Aszalos A., Schoenlein P.V., Currier S.J., Padmanabhan R., and Gottesman M.M. Laser scanning and confocal microscopy of daunorubicin, doxorubicin and rhodamine 123 in multidrug-resistant cells. Exp. Cell Res. 196 (1991) 323-329
205. Webb M., and Sorrentino B.P. Retroviral transfer of the human cytosolic aldehyde dehydrogenase gene as a means to generate cellular cyclophosphamide resistance. Blood 84 (1994) A1415
206. Weinstein R.S., Kuszak J.R., and Ashman J.B. P-glycoprotein is targeted to adhesion plaques, retraction fibers, and microspikes in drug resistant KB-V1 epidermoid carcinoma cells. J. Cell. Biol. 109 (1989) 324a
207. Williams D.A., Hsieh K., DeSilva A., and Mulligan R.C. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J. Exp. Med. 166 (1987) 210-218
208. + cells from Gaucher patients. Blood 86 (1995) 141-146
209. Zaman G.J.R., Flens M.J., van Leusden M.R., de Haas M., Mülder H.S., Lankelma J., Pinedo H.M., Scheper R.J., Baas F., Broxterman H.J., and Borst P. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA 91 (1994) 8822-8826
210. Zhang X.P., Ritke M.K., Yalowich J.C., Slovak M.L., Pelkey Ho J., Collins K.I., Annable T., Arceci R.J., Durr F.E., and Greenberger L.M. P-glycoprotein mediates profound resistance to bisantrene. Oncology Res. 6 (1994) 291-301
211. Zhao S.C., Li M.X., Banerjee D., Schweitzer B.I., Mineishi S., Gilboa E., and Bertino J.R. Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Ther. 1 (1994) 27-33
212. Zhou Y., Aran J., Gottesman M.M., and Pastan I. Co-expression of human adenosine deaminase and multidrug resistance using a bicistronic vector. Human Gene Ther. 9 (1998) 287-293
213. Zhou J.-Y., Chen D.-L., Shen Z.-S., and Koeffler P. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res. 50 (1990) 2031-2035